2022•Annals of OncologyOpen access

1399P Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Nishita Tripathi, Beverly Chigarira, Nicolas Sayegh, Vinay Mathew Thomas, Shruti Adidam Kumar, Divyam Goel, Clara Tandar, Taylor Ryan McFarland, Roberto Nussenzveig, D. Sirohi, Umang Swami, Benjamin Louis Maughan, Nivedita Agarwal

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Enzalutamide, Medicine, Androgen receptor, Prostate cancer, Docetaxel, Internal medicine, Oncology, Abiraterone

Back to paper search Browse research topics Original source

1399P Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) — Research Paper | ScholarLens